Bone Biologics Co. (NASDAQ:BBLG) Sees Large Decline in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 58,200 shares, a decrease of 19.3% from the October 31st total of 72,100 shares. Based on an average daily trading volume, of 3,010,000 shares, the short-interest ratio is currently 0.0 days. Approximately 10.9% of the company’s shares are short sold.

Bone Biologics Trading Down 3.2 %

BBLG traded down $0.04 during trading hours on Friday, reaching $1.22. The company’s stock had a trading volume of 99,011 shares, compared to its average volume of 1,471,036. The business’s 50-day moving average is $1.59 and its 200-day moving average is $1.54. Bone Biologics has a fifty-two week low of $0.80 and a fifty-two week high of $10.56.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.